A new HER2-directed antibody, zanidatamab (ZW25), is a bispecific monoclonal antibody that binds to two distinct extracellular epitopes of HER2 and is designed to elicit a cytotoxic T-lymphocyte response and antibody-dependent cell-mediated cytotoxicity against tumor cells overexpressing HER2 [40]. Here, ERBB2 is linked to neoplasm.